STUDY OBJECTIVES: To compare lung deposition of @entity7284 or @entity17013 administered from a novel, multidose inhalation device delivering liquid droplets (RESPIMAT; Boehringer Ingelheim Ltd; Bracknell, UK) or from conventional metered-dose inhalers (MDIs) with and without spacers. DESIGN: Two randomized, three-way crossover studies. SETTING: Clinical research laboratory. @entity1 : Healthy, nonsmoking volunteers. INTERVENTIONS: In one study, radiolabeled aerosols of @entity7284 from the RESPIMAT device and from a conventional @entity13521 with or without an Aerochamber spacer (Trudell Medical; London, Ontario @entity3394 ). In the second study, radiolabeled aerosols of @entity17013 from a RESPIMAT device, from a RESPIMAT device modified by inclusion of a baffle/impactor in the mouthpiece, and from a conventional @entity13521 with an Inhacort spacer (Boehringer Ingelheim; Ingelheim, Germany). MEASUREMENTS AND RESULTS: Assessment of the deposition of @entity7284 or @entity17013 in the lung and oropharynx using gamma scintigraphy. Safety was assessed based on reported adverse effects and spirometry (FEV1, FVC, and peak expiratory flow rate) to detect any paradoxical bronchoconstriction. The RESPIMAT device delivered significantly more @entity7284 to the lungs than either an @entity13521 alone or an @entity13521 with Aerochamber (39.2% vs 11.0% and 9.9% of metered dose, respectively; p<0.01). Oropharyngeal deposition of @entity7284 from the new device was lower than that from the @entity13521 (37.1% vs 71.7%, respectively; p<0.01). The RESPIMAT device deposited significantly more @entity17013 in the lungs compared with @entity13521 plus spacer (44.6% vs 26.4%, respectively; p<0.01), while resulting in similar oropharyngeal deposition (26.2% vs 31.2%, respectively). Introduction of a baffle into the RESPIMAT system reduced lung deposition of @entity17013 to 29.5%, and oropharyngeal deposition to 7.8% (p<0.01). CONCLUSION: The RESPIMAT device may prove to be an effective alternative to MDIs for the administration of inhaled bronchodilators and corticosteroids. The high lung deposition and low oropharyngeal deposition may lead to improved efficacy and tolerability of inhaled medications, especially @entity288 .

Lung deposition of @entity7284 and XXXX delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices.

@entity1 :: ('9606', 'Species') :: ['PARTICIPANTS'] @entity7284 :: ('MESH:D005280', 'Chemical') :: ['fenoterol'] @entity17013 :: ('MESH:C007734', 'Chemical') :: ['flunisolide'] @entity3394 :: ('MESH:D044483', 'Disease') :: ['Canada'] @entity13521 :: ('MESH:C564108', 'Disease') :: ['MDI'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity17013 :: (MESH:C007734,Chemical) :: ['flunisolide']
